Literature DB >> 22914529

A prospective study of total and ionized serum calcium and time to fatal prostate cancer.

Gary G Schwartz1, Halcyon G Skinner.   

Abstract

BACKGROUND: Higher levels of total and ionized serum calcium have been shown to predict fatal prostate cancer in prospective studies. Because the follow-up time in these studies was relatively short, these associations could reflect the effect of clinically significant but occult prostate tumors on serum calcium levels. If this were true, prostate cancer mortality rates among men with higher levels of serum calcium should be higher during the early follow-up period and should decline thereafter.
METHODS: We tested this hypothesis by estimating the relative risk of death from prostate cancer in the National Health and Nutrition Examination Survey III for incremental increases in total and ionized serum calcium using Cox proportional hazards regression with time-dependent effects.
RESULTS: Forty-nine (49) fatal prostate cancers occurred over 204 months of follow-up and 1,069,327 person-months of observation. Men with higher total serum calcium and higher serum ionized calcium had increased risks of fatal prostate cancer during the first 96 months of follow-up [Relative Hazard (RH) = 1.50 per 0.1 mmol/L total serum calcium, 95% confidence interval (CI) = 1.04-2.17; RH = 1.72 per 0.05 mmol/L ionized calcium, 95% CI = 1.11-2.66]. Evidence of an association between total and ionized serum calcium and prostate cancer deaths was not significant after 96 months.
CONCLUSIONS: Our analyses support the hypothesis that the elevated risk for fatal prostate cancer observed in men with high serum calcium is because of the presence of extant, but occult prostate cancer. IMPACT: These findings have implications for the potential use of serum calcium in the detection of clinically significant prostate cancer. 2012 AACR

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22914529     DOI: 10.1158/1055-9965.EPI-12-0585

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  12 in total

Review 1.  Body mass index and mortality in prostate cancer patients: a dose-response meta-analysis.

Authors:  S Zhong; X Yan; Y Wu; X Zhang; L Chen; J Tang; J Zhao
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-01-12       Impact factor: 5.554

2.  Serum calcium improved systemic inflammation marker for predicting survival outcome in rectal cancer.

Authors:  Zhuokai Zhuang; Xiaolin Wang; Meijin Huang; Yanxin Luo; Huichuan Yu
Journal:  J Gastrointest Oncol       Date:  2021-04

3.  The association between pre-treatment serum 25-hydroxyvitamin D and survival in newly diagnosed stage IV prostate cancer.

Authors:  Digant Gupta; Kristen Trukova; Brenten Popiel; Carolyn Lammersfeld; Pankaj G Vashi
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

4.  ROS signaling by NADPH oxidase 5 modulates the proliferation and survival of prostate carcinoma cells.

Authors:  Monika Höll; Rafal Koziel; Georg Schäfer; Haymo Pircher; Alexander Pauck; Martin Hermann; Helmut Klocker; Pidder Jansen-Dürr; Natalie Sampson
Journal:  Mol Carcinog       Date:  2015-01-05       Impact factor: 4.784

5.  Race and BMI modify associations of calcium and vitamin D intake with prostate cancer.

Authors:  Ken Batai; Adam B Murphy; Maria Ruden; Jennifer Newsome; Ebony Shah; Michael A Dixon; Elizabeth T Jacobs; Courtney M P Hollowell; Chiledum Ahaghotu; Rick A Kittles
Journal:  BMC Cancer       Date:  2017-01-19       Impact factor: 4.430

6.  Increased Serum Calcium Level Promotes the Risk of Lymph Node Metastasis in Endometrial Cancer.

Authors:  Xing-Chen Li; Yang-Yang Dong; Yuan Cheng; Jing-Yi Zhou; Xiao Yang; Bo-Qiang Shen; Xiao-Tong Wu; Xiao-Ping Li; Jian-Liu Wang
Journal:  Cancer Manag Res       Date:  2020-06-25       Impact factor: 3.989

7.  An elevated preoperative serum calcium level is a significant predictor for positive peritoneal cytology in endometrial carcinoma.

Authors:  Xingchen Li; Yuan Cheng; Yangyang Dong; Boqiang Shen; Xiao Yang; Jiaqi Wang; Jingyi Zhou; Jianliu Wang
Journal:  Chin J Cancer Res       Date:  2019-12       Impact factor: 5.087

8.  Adherence to dietary and lifestyle recommendations and prostate cancer risk in the prostate testing for cancer and treatment (ProtecT) trial.

Authors:  Vanessa Er; J Athene Lane; Richard M Martin; Pauline Emmett; Rebecca Gilbert; Kerry N L Avery; Eleanor Walsh; Jenny L Donovan; David E Neal; Freddie C Hamdy; Mona Jeffreys
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07-13       Impact factor: 4.254

9.  Potential role of gastrointestinal microbiota composition in prostate cancer risk.

Authors:  E Susan Amirian; Joseph F Petrosino; Nadim J Ajami; Yanhong Liu; Martha P Mims; Michael E Scheurer
Journal:  Infect Agent Cancer       Date:  2013-11-04       Impact factor: 2.965

10.  Metabolic serum biomarkers for the prediction of cancer: a follow-up of the studies conducted in the Swedish AMORIS study.

Authors:  Cecilia Bosco; Wahyu Wulaningsih; Jennifer Melvin; Aida Santaolalla; Mario De Piano; Rhonda Arthur; Mieke Van Hemelrijck
Journal:  Ecancermedicalscience       Date:  2015-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.